Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invictus MD Strategies Corp IVITF

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.


GREY:IVITF - Post by User

Comment by gamos99on Sep 18, 2019 9:17pm
236 Views
Post# 30141612

RE:Share price the effect of manipulation by

RE:Share price the effect of manipulation by


It all depends on the closing date. Here's my take on the loan:

Trichome $6M loan to Acreage Pharms
it’s a 10% annual interest rate loan, matures in 24 months. Money is to complete Phase 3 at Acreage Pharms. Invictus is the guarantor of the loan.

Acreage gets $3M at the closing date (Sept. 13, 2019) and another $3M two months after the closing date.

In addition to paying back the loan, Invictus must issue to Trichome some “Bonus Shares” and “Bonus Warrants” (that’s what they’re called in the term sheet agreement)

Shares: the number of shares is  equal to 17% of loan amount (i.e. $1.02M) divided by $0.33, or the closing price of shares on Sept. 13th. That price was $0.25.
So, Invictus owes Trichome $1.02M/$0.25 = 4.08M shares.

Warrants: same as above, except 15% of loan amount  - so 3.6M warrants, exercisable at $0.25 each.Invictus has 125 M stares outstanding, so this will dilute the shares by about 6%.

Did Trichome drive the price down? Maybe. It would be smart if they did. But if I am correct in reading that the closing date was Sept. 13, 2019, then it’s done and won’t continue to pressure Invictus’ share price.

Here's the Trichome press release:

https://www.globenewswire.com/news-release/2019/08/27/1907455/0/en/ACREAGE-PHARMS-LTD-SIGNS-NON-BINDING-TERM-SHEET-FOR-UP-TO-6-MILLION-FINANCING-FROM-TRICHOME-FINANCIAL.html

<< Previous
Bullboard Posts
Next >>